Nexus Pharmaceuticals v. Somerset Pharma: Ephedrine Sulfate ANDA Dispute Settles After 662 Days
Nexus Pharmaceuticals filed suit in the District of New Jersey against Somerset Pharma over three patents protecting EMERPHED® ephedrine sulfate injection, targeting Somerset’s ANDA No. 218113. After 662 days of litigation, the parties reached a confidential settlement and license agreement, with all claims dismissed without prejudice.
EMERPHED® ANDA Battle Ends in Confidential License Deal
Nexus Pharmaceuticals, Inc. filed this Hatch-Waxman ANDA infringement action on 3 March 2023 in the U.S. District Court for the District of New Jersey. Nexus asserted three patents — US11,090,278, US11,478,436, and US11,426,369 — against Somerset Pharma, LLC and Somerset Therapeutics, LLC in connection with Somerset’s Abbreviated New Drug Application No. 218113, which seeks FDA approval to market a generic ephedrine sulfate injection product at the same 50mg/10mL (5mg/mL) concentration as Nexus’s branded EMERPHED® product.
The case terminated on 24 December 2024 through a stipulated dismissal without prejudice, reflecting a negotiated resolution documented in a confidential settlement and license agreement. The parties agreed to forgo further litigation on all claims, counterclaims, and affirmative defenses. Each side bears its own legal costs. The court retained jurisdiction to enforce or supervise performance under the settlement, which is a standard provision suggesting ongoing obligations — most likely a royalty-bearing or entry-date-limited license — exist between the parties.
At 662 days, the case ran longer than many ANDA disputes that settle early but shorter than those reaching full Markman or trial proceedings, suggesting substantive negotiations occurred before a commercial deal was struck. The confidential nature of the license terms means the public record does not reveal any permitted market-entry date, royalty structure, or exclusivity carve-outs. What is clear is that Somerset’s ANDA product remains subject to the settlement agreement’s constraints, and the court’s retained jurisdiction indicates Nexus maintains ongoing enforcement leverage.
Filing to Dismissed without Prejudice in 662 days
662 days — above the median for ANDA patent cases resolved before trial in D.N.J.
Confidential settlement reached: what the dismissal without prejudice means
Dismissal without prejudice under a settlement and license agreement
A dismissal without prejudice means neither party obtained a merits ruling. The claims are ended for now but could theoretically be re-filed. Here, the dismissal is paired with a confidential settlement and license agreement, and the court retains jurisdiction to enforce it — meaning any breach of the license could be addressed without a new filing. This is the standard structure for Hatch-Waxman settlements that include forward-looking commercial terms.
No merits adjudicationNexus preserves patent validity and gains a licensed framework
Nexus exits without any adverse ruling on validity or enforceability of its three ephedrine sulfate patents. The patents-in-suit remain unchallenged on the merits and fully enforceable against third parties. The confidential license likely provides Nexus with commercial protections — such as a delayed market-entry date for Somerset — while generating potential royalty income. The court’s retained jurisdiction preserves Nexus’s ability to enforce compliance.
Patents intact, license securedSomerset obtains a license but on undisclosed terms
Somerset avoids an adverse infringement finding and likely secures a pathway to market for its ANDA No. 218113 product, though the timing and conditions are not disclosed. The dismissal without prejudice means Somerset did not extract a finding of invalidity or non-infringement that would benefit other generic challengers. Any future deviation from the license terms could trigger enforcement proceedings before the same court without a fresh complaint.
Licensed entry, terms confidentialEphedrine sulfate market entry date remains opaque for third parties
Because the settlement is confidential and no merits ruling was issued, competing generic manufacturers receive no public guidance on the validity of Nexus’s three patents. Any other ANDA filer targeting ephedrine sulfate injection at this concentration must independently assess infringement risk against US11090278, US11478436, and US11426369. The retained-jurisdiction clause and surviving patent portfolio signal that Nexus intends to actively defend its EMERPHED® franchise against future challengers.
No public precedent setFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Nexus Pharmaceuticals, Inc. | Company | Pharmaceutical company and NDA holder — asserting US11426369, US11478436, and US11090278Search in Eureka ↗ |
| Defendant | SOMERSET PHARMA, LLC | Company | Generic pharmaceutical manufacturer seeking FDA ANDA approval for ephedrine sulfate injectionSearch in Eureka ↗ |
| Plaintiff counsel | Ahmed Muhammad Tan Riaz | Attorney | Counsel for Nexus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Justin Taylor Quinn | Attorney | Counsel for Nexus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Michael James Gesualdo | Attorney | Counsel for Nexus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | ArentFox Schiff LLP | Law Firm | Representing Nexus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Robinson Miller LLC | Law Firm | Representing Nexus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Eric I. Abraham | Attorney | Counsel for SOMERSET PHARMA, LLCSearch in Eureka ↗ |
| Defendant counsel | Kristine L. Butler | Attorney | Counsel for SOMERSET PHARMA, LLCSearch in Eureka ↗ |
| Defendant counsel | William Murtha | Attorney | Counsel for SOMERSET PHARMA, LLCSearch in Eureka ↗ |
| Defendant law firm | Hill Wallack LLP | Law Firm | Representing SOMERSET PHARMA, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated judgment records a fully negotiated resolution rather than a judicial determination on infringement, validity, or enforceability. The language confirms the court’s jurisdictional basis and identifies the three patents-in-suit and the specific ANDA product, but expressly notes that all claims and counterclaims are dismissed without prejudice pursuant to a confidential agreement. No findings of fact or conclusions of law were entered, meaning the verdict carries no precedential weight on the merits. The retained-jurisdiction clause is the operative operative mechanism going forward.
US11426369B2 & US11478436B2 — Ephedrine Sulfate Injection Formulations
The patents-in-suit — US11,090,278, US11,478,436, and US11,426,369 — collectively protect aspects of Nexus’s EMERPHED® product: an ephedrine sulfate injection at a concentration of 50mg/10mL (5mg/mL) intended for intravenous use. Application numbers US17/556,904 and US17/738,557 indicate relatively recent prosecution, with both applications filed in the 2021–2022 window, conferring patent terms likely extending into the late 2030s. The patents sit within the pharmaceutical formulation and injectable drug delivery domain.
Ephedrine sulfate injection is a vasopressor used primarily to treat hypotension during anesthesia, a market that expanded significantly following the FDA’s 2019 approval of EMERPHED® as a ready-to-use formulation. The three-patent portfolio creates overlapping layers of protection — a common lifecycle management strategy — meaning a generic challenger must successfully invalidate or design around all three to market a competing product without a license. This layered approach, combined with the confidential Somerset license, positions Nexus to maintain branded pricing power and negotiate future licenses from a position of strength.
Should your team run an FTO against US11426369B2 and US11478436B2?
Any pharmaceutical company with an active or planned ANDA targeting ephedrine sulfate injection at 50mg/10mL should treat these three patents as high-priority FTO targets. The Somerset settlement confirms Nexus’s willingness to enforce aggressively. Formulation teams developing ready-to-use vasopressor injectables — including alternative concentrations or excipient profiles — should map their compositions against the claims of all three patents before submitting to the FDA, not after receiving a Paragraph IV certification challenge.
PatSnap Eureka’s FTO Search Agent can map your candidate formulation’s technical parameters against the independent and dependent claims of US11090278, US11478436, and US11426369 in parallel, flagging overlap risk and surfacing relevant prior art that may support design-around or invalidity arguments. Eureka’s patent family analysis will also identify any divisional or continuation applications that may extend Nexus’s protection beyond the three asserted patents, giving your regulatory and IP teams a complete clearance picture before you commit to an ANDA filing.
Run a freedom-to-operate analysis on US11426369B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA Patent Infringement Cases in Pharmaceutical Injectables
Explore comparable Hatch-Waxman infringement actions involving injectable drug formulation patents litigated in the District of New Jersey and related federal courts.
What this case signals for the injectable pharmaceutical IP landscape
A confidential settlement with retained jurisdiction is a strategic outcome — it resolves litigation while preserving maximum future leverage for the patent holder.
Three-patent assertion creates a high invalidation burden for future generic filers
Nexus asserted three distinct patents covering ephedrine sulfate injection. Any generic entrant must challenge or design around all three to clear the path. The settlement leaves all three patents valid and enforceable, raising the ante for any subsequent ANDA filer who cannot negotiate comparable license terms.
Retained court jurisdiction is a litigation tool, not just boilerplate
The stipulated order expressly preserves the New Jersey court’s jurisdiction to enforce the settlement. This provision is commercially significant: if Somerset deviates from agreed market-entry timelines or royalty obligations, Nexus can seek enforcement without re-filing a new infringement action, compressing the time to relief substantially.
Nexus v SOMERSET — key questions answered
Nexus asserted three patents: US11,090,278, US11,478,436 (application US17/738557), and US11,426,369 (application US17/556904). All three relate to ephedrine sulfate injection formulations covering Nexus’s EMERPHED® 50mg/10mL product. The case was filed 3 March 2023 in the District of New Jersey.
The case settled on 24 December 2024 after 662 days. The parties entered a confidential settlement and license agreement. All claims and counterclaims were dismissed without prejudice, each side bears its own costs, and the court retained jurisdiction to enforce the settlement. No merits ruling was issued.
ANDA No. 218113 is Somerset Pharma’s abbreviated new drug application seeking FDA approval for a generic ephedrine sulfate injection at 50mg/10mL (5mg/mL) — the same concentration as Nexus’s branded EMERPHED® product. Nexus’s infringement suit targeted this ANDA under the Hatch-Waxman framework.
A dismissal without prejudice means no court ruled on infringement, validity, or enforceability. Claims could theoretically be re-filed, though in practice the confidential settlement agreement governs the parties’ future conduct. The court’s retained jurisdiction means Nexus can seek enforcement of settlement terms without filing a new lawsuit if Somerset breaches the agreement.
The settlement creates no public precedent on the validity or scope of Nexus’s three patents. Competing ANDA filers must independently assess infringement risk against all three patents. The settlement confirms Nexus’s enforcement posture but provides no public guidance on claim scope, leaving the legal landscape unchanged for third-party generic entrants.
PatSnap Eureka searches patents and litigation data to answer instantly.